Smalley KS - Search Results

1

Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia.

Johnson DB, Smalley KS, Sosman JA. Johnson DB, et al. Among authors: smalley ks. Clin Cancer Res. 2014 Aug 15;20(16):4186-92. doi: 10.1158/1078-0432.CCR-13-3270. Epub 2014 Jun 3. Clin Cancer Res. 2014. PMID: 24895460 Free PMC article. Review.

2

Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy.

Smalley KS, Herlyn M. Smalley KS, et al. Int J Cancer. 2009 Mar 15;124(6):1245-50. doi: 10.1002/ijc.24129. Int J Cancer. 2009. PMID: 19089923 Free article. Review.

3

Integrating BRAF/MEK inhibitors into combination therapy for melanoma.

Smalley KS, Flaherty KT. Smalley KS, et al. Br J Cancer. 2009 Feb 10;100(3):431-5. doi: 10.1038/sj.bjc.6604891. Epub 2009 Jan 20. Br J Cancer. 2009. PMID: 19156138 Free PMC article. Review.

4

Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.

Smalley KS, Nathanson KL, Flaherty KT. Smalley KS, et al. Cancer Res. 2009 Apr 15;69(8):3241-4. doi: 10.1158/0008-5472.CAN-08-4305. Epub 2009 Apr 7. Cancer Res. 2009. PMID: 19351826 Review.

5

Understanding melanoma signaling networks as the basis for molecular targeted therapy.

Smalley KS. Smalley KS. J Invest Dermatol. 2010 Jan;130(1):28-37. doi: 10.1038/jid.2009.177. J Invest Dermatol. 2010. PMID: 19571822 Free article.

6

Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.

Sondak VK, Smalley K. Sondak VK, et al. Pigment Cell Melanoma Res. 2009 Aug;22(4):386-7. doi: 10.1111/j.1755-148X.2009.00593.x. Pigment Cell Melanoma Res. 2009. PMID: 19624312 No abstract available.

7

PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.

Smalley KS. Smalley KS. Curr Opin Investig Drugs. 2010 Jun;11(6):699-706. Curr Opin Investig Drugs. 2010. PMID: 20496265 Review.

8

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KS. Paraiso KH, et al. Among authors: smalley ks. Br J Cancer. 2010 Jun 8;102(12):1724-30. doi: 10.1038/sj.bjc.6605714. Br J Cancer. 2010. PMID: 20531415 Free PMC article.

9

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.

Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS. Paraiso KH, et al. Among authors: smalley ks. Cancer Res. 2011 Apr 1;71(7):2750-60. doi: 10.1158/0008-5472.CAN-10-2954. Epub 2011 Feb 11. Cancer Res. 2011. PMID: 21317224 Free PMC article.

10

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

Fedorenko IV, Paraiso KH, Smalley KS. Fedorenko IV, et al. Among authors: smalley ks. Biochem Pharmacol. 2011 Aug 1;82(3):201-9. doi: 10.1016/j.bcp.2011.05.015. Epub 2011 May 25. Biochem Pharmacol. 2011. PMID: 21635872 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

200 results

Search Page